Product Liability Practice: DLA Piper

Law360, New York (July 18, 2008, 12:00 AM EDT) -- Heightened scrutiny of the pharmaceutical and medical device industry by Congress and the U.S. Food and Drug Administration isn't going to decline anytime soon, said partners in DLA Piper's product liability and toxic torts group.

“There's been an uptick in safety issues raised publicly, with Vioxx being the best example,” said Loren Brown, a partner with the firm's global litigation practice who concentrates in the pharmaceutical and mass tort areas. “We're starting to see less tolerance for risk on the part of the public, and Congress...
To view the full article, register now.